阿爾茨海默病認(rèn)知功能量表述評(píng)

　2．療效評(píng)價(jià)［19,20］：在乙酰膽堿酯酶抑制劑特可林（tacrine）、velnacrine 、毒扁豆堿（physostigmine）、多奈哌齊（donepezil）和rivastigmine治療輕-中度AD的大樣本、多中心、隨機(jī)、雙盲、安慰劑對(duì)照臨床試驗(yàn)中，療效評(píng)價(jià)均采用MMSE、ADAS-cog分測(cè)驗(yàn)和臨床晤談總體印象量表。Arrieta等［20］總結(jié)1981～1997年公開發(fā)表的49篇特可林治療AD的論文，應(yīng)用的評(píng)定工具為：MMSE 16篇，ADAS 4篇，3MS、CASI、AVLT等均有報(bào)道。

　　　　六、幾點(diǎn)說明

　　　　1． 上述量表對(duì)于確定癡呆的病因即鑒別診斷方面作用有限。

　　2． 從55或60歲開始縱向隨訪認(rèn)知功能十分重要，尤其是教育程度比較高的老人。

　　3． 認(rèn)知評(píng)定只能作為AD診斷的輔助工具，臨床診斷必須結(jié)合日�；顒�(dòng)能力量表、非認(rèn)知行為問卷、總體嚴(yán)重度量表、照料者負(fù)擔(dān)量表及腦影像學(xué)、電生理學(xué)、生化學(xué)檢查結(jié)果，最后確診依賴于隨訪和病理檢查。

　　4. 軀體狀況不佳、情緒障礙、意識(shí)不清、受試者不配合等都可以影響認(rèn)知檢查結(jié)果。

　　5. 時(shí)代在發(fā)展，人口的年齡結(jié)構(gòu)和老人素質(zhì)處在變化之中，對(duì)認(rèn)知功能的認(rèn)識(shí)也在深化，故評(píng)定工具也需要不斷修訂以適應(yīng)新的要求。由于知識(shí)產(chǎn)權(quán)等原因，上述大部分測(cè)驗(yàn)沒有引進(jìn)。我們介紹這些評(píng)定方法，供國內(nèi)同道在量表編制與使用時(shí)參考。

　　參考文獻(xiàn)
　　　1，Tierney MC, Szalai JP, Snow WG, et al. Domain specificity of the subtests of the mini-mental state examination. Arch Neurol, 1997,54:713-716.

　　2，Stuss DT,Meiran N,Guzman DA，et al. Do long tests yield a more accurate diagnosis of dementia than short tests Arch Neurol, 1996,53:1033-1039.

　　3，鄭瞻培. 修改后的長谷川簡易智能評(píng)定量表. 國外醫(yī)學(xué)精神病學(xué)分冊(cè)，1993，20： 40-41.

　　4，Royall DR, Cordes JA, Polk M. CLOX: an executive clock drawing task. J Neurol Neurosurg Psychiatry, 1998, 64:588-594.

　　5，Solomon PR, Hirschoff A, Kelly B, et al. A 7 minute neurocognitive screening battery: highly sensitive to Alzheimer′s disease. Arch Neurol, 1998, 55:349-355.

　　6，Lezak MD. Neuropsychological assessment.2nd ed. New York: Oxford University Press, 1983.578-581.

　　7，Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer′s disease. Am J Psychiatry, 1984, 141:1356-1364.

　　8，Kiernan RJ, Mueller J, Langston JW, et al. The neurobehavioral cognitive status examination: a quantitative approach to cognitive assessment. Ann Intern Med,1987,107:481-485.

　　9，Osmon DC, Smet IC, Winegarden B,et al. Neurobehavioral cognitive status examination: its use with unilateral stroke patients in a rehabilitation setting. Arch Phs Med Rehabil, 1992,73:414-418.

　　10，F(xiàn)aust D, Fogel B. The development and initial validation of a sensitive bedside cognitive screening test. J Nerv Ment Dis, 1989, 177:25-31.

　　11，Glosser G, Wolfe N, Kliner-Krenzel L, et al. Cross-cultural cognitive examination performance in patients with Parkinson′s disease and Alzheimer′s disease. J Nerv Ment Dis, 1994, 182: 432-436.

　　12，Mate-Kole CC, Major A, Lenzer I, et al. Validation of the quick cognitive screening test. Arch Phys Med Rehabil, 1994,75:867-875.

　　13，Delis DC. Neuropsychological assessment of learning and memory. In: Boller F, Grafman J, eds. Handbook of Neuropsychology. vol.3. New York: Elsevier Science Publishers B.V. （Biomedical Division）, 1989.3-30.

14，Chan AS,Salmon DP,Butters N, et al. Semantic network abnormality predicts rate of cognitive decline in patients with probable Alzheimer′s disease. J Int Neuropsychol Soc, 1995, 1:297-303.

　　15，Chan AS,Butters N,Salmon DP. The deterioration of semantic networks in patients with Alzheimer′s disease: a cross-sectional study. Neuropsychologia, 1997, 35:241-248.

　　16，Morris JC,Heyman A,Mohs RC,et al. The Consortium to Establish a Registry for Alzheimer′s Disease（CERAD）. Part I. Clinical and neuropsychological assessment of Alzheimer′s disease. Neurology, 1989,39:1159-1165.

　　17，Almkvist O. Neuropsychological features of early Alzheimer′s disease: preclinical and clinical stages. Acta Neurol Scand, 1996, 165 Suppl: 63-71.

　　18，Pasquier F. Early diagnosis of dementia: neuropsychology. J Neurol, 1999,246:5-15.

　　19，F(xiàn)rancis PT,Palmer AM,Snape M, et al. The cholinergic hypothesis of Alzhemer′s disease: a review of progress. J Neurol Neurosurg Psychiatry, 1999, 66:137-147.

　　20，Arrieta JL, Artalejo FR. Methodology,results and quality of clinical trials of tacrine in the treatment of Alzheimer disease: a systematic review of the literature. Age Aging, 1998,27:161-179.

上一頁  [1] [2]